title: Lung cancer in 2016: immunotherapy comes of age.
authors.affiliation: Olivia Newton-John Cancer and Wellness Centre, Austin Health and Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia. Electronic address: paul.mitchell@austin.org.au.
authors.forename: Paul L R
authors.initials: PL
authors.lastname: Mitchell
authors.affiliation: Olivia Newton-John Cancer and Wellness Centre, Austin Health and Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
authors.forename: Thomas
authors.initials: T
authors.lastname: John
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab; D000077594:Nivolumab; C582435:pembrolizumab